Cutaneous basal cell carcinoma cells express bone morphogenetic protein (BMP) 2 and 4, while GREMLIN 1, a BMP antagonist is highly expressed in the stroma of the tumour but not in the dermis underlying normal keratinocytes. Here, GREM1 is linked to basal cell carcinoma.